Today's Low
₹ 158.20
Today's High
₹ 164.45
52 Weeks Low
₹ 68.35
52 Weeks High
₹ 193.75
Lower
₹ 127.15
Upper
₹ 190.65
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti-platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti-malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, anti-fungal, anti-inflammatory/analgesic/anti-pyretic, anti-diabetic, cardiac, vitamins, topical steroids/corticosteroids, and other formulations. In addition, it offers veterinary pharmaceutical, nutraceutical, oncology, herbal, and surgical products. The company was founded in 1989 and is headquartered in Mumbai, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 76.4 | 81.3 | 61.2 | 63.0 | 59.1 | 39.9 | 47.3 | 43.7 | 51.8 | 47.6 | 33.7 |
Total Non-Current Assets | 5.0 | 4.7 | 4.9 | 5.7 | 5.1 | 4.8 | 2.2 | 2.1 | 1.7 | 1.0 | 0.9 |
Total Assets | 81.5 | 86.0 | 66.1 | 68.6 | 64.1 | 44.7 | 49.4 | 45.8 | 53.4 | 48.6 | 34.6 |
Total Current Liabilities | 51.9 | 59.3 | 40.4 | 42.5 | 40.8 | 37.3 | 41.6 | 34.2 | 47.2 | 42.9 | 29.7 |
Total Non-Current Liabilities | 3.2 | 4.3 | 4.3 | 4.8 | 2.7 | 3.4 | 4.6 | 8.4 | 3.2 | 2.9 | 3.0 |
Shareholder's Funds | 26.4 | 22.4 | 21.4 | 21.4 | 20.6 | 4.0 | 3.2 | 3.2 | 3.1 | 2.8 | 1.8 |
Total Liabilities | 81.5 | 86.0 | 66.1 | 68.6 | 64.1 | 44.7 | 49.4 | 45.8 | 53.4 | 48.6 | 34.6 |
The Industry Quick Ratio stands at 1.77, vs the Quick Ratio of 2.17, which results in a Positive aspect.
The Industry Debt to Equity Ratio stands at 0.20, vs the Debt to Equity Ratio of 0.41, which results in a Negative aspect.
The Industry Price to BV stands at 6.01, vs the Price to BV of 4.43, which results in a Negative aspect.
The Industry Current Ratio stands at 2.53, vs the Current Ratio of 2.27, which results in a Negative aspect.
Particulars | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 75.8 | 53.8 | 60.1 | 75.1 | 67.8 | 64.0 | 66.7 | 94.6 | 120.7 | 118.8 | 81.6 |
Total Expenditure | 68.9 | 51.1 | 59.2 | 73.0 | 65.0 | 60.5 | 66.2 | 94.9 | 118.2 | 117.2 | 81.0 |
Operating Profit(Excl OI) | 8.7 | 4.5 | 3.1 | 4.1 | 4.5 | 4.4 | 3.7 | 4.0 | 3.3 | 1.9 | 0.6 |
Add: Other Income | 1.8 | 1.8 | 2.2 | 2.0 | 1.7 | 0.9 | 3.2 | 4.3 | 0.9 | 0.3 | 0.0 |
Operating Profit | 8.7 | 4.5 | 3.1 | 4.1 | 4.5 | 4.4 | 3.7 | 4.0 | 3.3 | 1.9 | 0.6 |
Less: Interest | 2.5 | 2.6 | 2.6 | 2.7 | 2.9 | 3.1 | 3.4 | 3.4 | 2.7 | 0.9 | 0.0 |
PBDT | 6.2 | 1.8 | 0.5 | 1.4 | 1.6 | 1.3 | 0.4 | 0.6 | 0.7 | 0.9 | 0.6 |
Less: Depreciation Amortization | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.0 | 0.0 | 0.0 |
PBT & Exceptional Items | 5.7 | 1.4 | 0.1 | 1.1 | 1.4 | 1.0 | 0.0 | 0.2 | 0.6 | 0.9 | 0.6 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | 5.7 | 1.4 | 0.1 | 1.1 | 1.4 | 1.0 | 0.0 | 0.2 | 0.6 | 0.9 | 0.6 |
Less: Taxation | 1.7 | 0.4 | 0.1 | 0.4 | 0.6 | 0.3 | 0.0 | 0.0 | 0.3 | 0.3 | 0.2 |
Profit After Tax | 4.0 | 1.1 | 0.0 | 0.7 | 0.8 | 0.7 | 0.0 | 0.2 | 0.3 | 0.6 | 0.4 |
Earnings Per Share | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry PE Ratio stands at 42.40, vs the PE Ratio of 29.29, which results in a Negative aspect.
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PAT Growth stands at 41.10, vs the PAT Growth of 64.12, which results in a Positive aspect.
The Industry PAT Margin stands at 9.68, vs the PAT Margin of 9.48, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 8.8 | 5.7 | 1.4 | 0.1 | 1.1 | 1.3 | 1.0 | 0.0 | 0.2 | 0.6 | 0.9 | 0.0 |
Tax Paid | -1.6 | -0.8 | -0.1 | -0.7 | -0.1 | -0.4 | -0.1 | 0.0 | -0.1 | -0.2 | -0.3 | 0.0 |
Adjustment | 1.2 | 1.6 | 3.4 | 5.8 | 1.7 | 1.6 | 2.5 | 0.6 | 0.3 | 2.3 | 0.8 | 0.0 |
Changes In Working Capital | 8.8 | 5.7 | 1.4 | 0.1 | 1.1 | 1.3 | 1.0 | 0.0 | 0.2 | 0.6 | 0.9 | 0.0 |
Cash Flow after changes in Working Capital | 2.6 | 2.1 | 2.1 | 3.9 | 4.4 | -9.1 | 0.5 | 4.6 | -3.6 | -6.8 | 4.1 | 0.0 |
Cash Flow from Operating Activities | 1.1 | 1.3 | 2.0 | 3.2 | 4.3 | -9.5 | 0.5 | 4.6 | -3.7 | -7.0 | 3.8 | 0.0 |
Cash Flow from Investing Activities | 0.3 | -0.8 | -0.1 | 0.0 | -0.3 | 1.1 | 0.7 | 3.1 | 1.8 | -0.2 | 0.1 | 0.0 |
Cash Flow from Financing Activities | -1.7 | 0.4 | -1.8 | -3.1 | -4.0 | 8.5 | -1.2 | -7.6 | 1.9 | 6.5 | -3.6 | 0.0 |
Net Cash Inflow / Outflow | -0.4 | 0.9 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | -0.8 | 0.3 | 0.0 |
Opening Cash & Cash Equivalents | 1.4 | 0.5 | 0.4 | 0.3 | 0.3 | 0.2 | 0.2 | 1.0 | 1.0 | 1.8 | 1.5 | 0.0 |
Closing Cash & Cash Equivalent | 1.0 | 1.4 | 0.5 | 0.4 | 0.3 | 0.3 | 0.2 | 1.0 | 1.0 | 1.0 | 1.8 | 0.0 |
The Industry PFCF Ratio stands at 37.73, vs the PFCF Ratio of -278.75, which results in a Negative aspect.
The Industry PCF RATIO stands at 27.04, vs the PCF RATIO of 142.52, which results in a Positive aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 279.0 | 125.7 | 134.2 | 262.4 | 200.9 | 131.6 | 101.8 | 254.1 | 222.8 | 198.6 | 82.7 | 188.8 | 213.0 | 100.3 | 35.7 |
Total Income | 283.7 | 128.6 | 137.8 | 267.7 | 206.2 | 139.0 | 106.1 | 259.6 | 225.9 | 202.3 | 88.4 | 194.6 | 216.2 | 104.0 | 41.1 |
Total Expenditure | 249.4 | 99.1 | 111.1 | 254.6 | 165.3 | 105.7 | 79.8 | 245.3 | 197.9 | 176.5 | 70.0 | 202.4 | 186.0 | 87.4 | 35.6 |
PBIDT (Excl OI) | 29.5 | 26.6 | 23.1 | 7.8 | 35.6 | 25.9 | 22.0 | 8.8 | 24.9 | 22.2 | 12.7 | -13.6 | 27.0 | 12.9 | 0.1 |
Other Income | 4.7 | 3.0 | 3.6 | 5.3 | 5.3 | 7.4 | 4.3 | 5.5 | 3.1 | 3.7 | 5.7 | 5.7 | 3.2 | 3.7 | 5.4 |
Operating Profit | 34.2 | 29.6 | 26.7 | 13.1 | 40.9 | 33.3 | 26.3 | 14.3 | 27.9 | 25.8 | 18.4 | -7.9 | 30.2 | 16.6 | 5.5 |
Interest | 4.4 | 4.7 | 4.3 | 5.4 | 4.2 | 5.3 | 5.3 | 6.5 | 5.5 | 6.1 | 6.5 | 10.7 | 5.9 | 5.1 | 4.4 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 29.9 | 24.8 | 22.4 | 7.7 | 36.7 | 28.0 | 21.0 | 7.9 | 22.5 | 19.7 | 11.9 | -18.5 | 24.3 | 11.5 | 1.1 |
Depreciation | 1.2 | 1.2 | 1.2 | 1.5 | 1.2 | 1.4 | 0.9 | 1.5 | 1.0 | 1.0 | 1.0 | 1.1 | 1.1 | 1.1 | 1.0 |
Profit Before Tax | 28.6 | 23.6 | 21.2 | 6.2 | 35.5 | 26.6 | 20.2 | 6.4 | 21.4 | 18.7 | 10.8 | -19.7 | 23.3 | 10.4 | 0.0 |
Tax | 7.5 | 6.6 | 5.3 | 1.9 | 8.9 | 6.7 | 5.0 | 4.3 | 5.4 | 4.7 | 2.7 | -5.2 | 6.1 | 2.7 | 0.0 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 21.1 | 17.0 | 15.9 | 4.4 | 26.6 | 19.9 | 15.1 | 2.0 | 16.1 | 14.0 | 8.1 | -14.5 | 17.2 | 7.7 | 0.0 |
Net Profit | 21.1 | 17.0 | 15.9 | 4.4 | 26.6 | 19.9 | 15.1 | 2.0 | 16.1 | 14.0 | 8.1 | -14.5 | 17.2 | 7.7 | 0.0 |
ADDITIONAL INFOS: | |||||||||||||||
Equity Capital | 106.0 | 106.0 | 106.0 | 105.5 | 105.5 | 105.5 | 105.5 | 105.5 | 105.5 | 105.5 | 105.5 | 105.5 | 105.5 | 105.5 | 105.5 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 2.0 | 1.6 | 1.5 | 0.4 | 2.5 | 1.9 | 1.4 | 0.2 | 1.5 | 1.3 | 0.8 | -1.4 | 1.6 | 0.7 | 0.0 |
Operating Profit Margin | 12.3 | 23.5 | 19.9 | 5.0 | 20.3 | 25.3 | 25.9 | 5.6 | 12.5 | 13.0 | 22.2 | -4.2 | 14.2 | 16.6 | 15.4 |
Net Profit Margin | 7.6 | 13.6 | 11.8 | 1.7 | 13.3 | 15.2 | 14.9 | 0.8 | 7.2 | 7.0 | 9.8 | -7.7 | 8.1 | 7.7 | 0.1 |
The Industry Net Sales Growth stands at 10.00, vs the Net Sales Growth of -8.12, which results in a Negative aspect.
The Industry Mcap Growth stands at -4.23, vs the Mcap Growth of 120.56, which results in a Positive aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 173.15 | 180.56 | 163.22 |
R3 | 170.10 | 169.73 | 161.33 |
R2 | 167.05 | 166.86 | 160.71 |
R1 | 163.25 | 162.88 | 160.08 |
Pivot | 160.20 | 160.01 | 160.20 |
S1 | 156.40 | 156.03 | 158.82 |
S2 | 153.35 | 153.16 | 158.19 |
S3 | 149.55 | 149.18 | 157.57 |
S4 | 145.75 | 139.46 | 155.68 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
58.76
Neutral
RSI
52.58
Neutral
ROC
7.75
Bullish
UltimateOscillator
47.94
Neutral
Williams Indicator
-42.64
Neutral
CCI Indicator
57.26
Neutral
MACD
-2,809.14
Bearish
Stochastic Indicator
61.80
Neutral
ATR
9.34
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
02-02-2024 | Financial Results |
08-11-2023 | Financial Results |
07-08-2023 | VAISHALI PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 07-Aug-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended June 2023 . |
22-05-2023 | Financial Results/Other business matters |
06-02-2023 | To consider and approve the Standalone Un-Audited Financial Result for the quarter and nine months ended December 2022 |
05-12-2022 | Fund raising |
03-11-2022 | Financial results |
25-07-2022 | Financial results |
30-05-2022 | Financial results |
04-05-2022 | Fund raising |
21-01-2022 | Financial Results |
10-11-2021 | Financial Results |
24-07-2021 | Financial Results |
10-07-2021 | Fund Raising/Other business matters |
14-05-2021 | Financial Results/Other business matters |